Pre-diabetes — an A1C between 5.7% and 6.4%, or fasting glucose between 100 and 125 mg/dL — now qualifies many patients for GLP-1 prescriptions even at lower BMI thresholds. The eligibility landscape has shifted meaningfully in 2026.
Why Pre-Diabetes Matters for GLP-1 Eligibility
Pre-diabetes is a recognized weight-related comorbidity. Under standard prescribing criteria, a patient with a BMI of 27 to 29.9 and a pre-diabetes diagnosis meets the threshold for GLP-1 therapy.
This is significant because pre-diabetes affects an estimated 98 million American adults. Many of these individuals have BMIs in the 27 to 30 range — previously a gray zone for GLP-1 access — but now have a clear clinical pathway.
The Clinical Evidence
The evidence supporting GLP-1 therapy for pre-diabetes is robust. Semaglutide and tirzepatide have both demonstrated significant reductions in progression from pre-diabetes to type 2 diabetes in clinical trials. The SELECT trial showed cardiovascular benefits for patients with obesity and existing cardiovascular disease, further supporting early intervention.
Additionally, the STEP trials demonstrated that patients with pre-diabetes who received semaglutide had a dramatically higher rate of returning to normoglycemia compared to placebo — meaning GLP-1 therapy may help reverse pre-diabetic status entirely in some patients.
What Counts as Pre-Diabetes
A1C between 5.7% and 6.4%, fasting plasma glucose between 100 and 125 mg/dL, or an oral glucose tolerance test (OGTT) result between 140 and 199 mg/dL. Any of these lab values can establish a pre-diabetes diagnosis.
How to Use Pre-Diabetes to Qualify
If you suspect you may have pre-diabetes, the first step is lab work. An A1C test and fasting glucose are simple, inexpensive blood tests that most primary care providers and telehealth platforms can order.
Once you have a documented pre-diabetes diagnosis, you meet the comorbidity requirement for GLP-1 prescriptions at a BMI of 27 or above. This applies to both brand-name and compounded medications.
Insurance Implications
For insurance coverage of brand-name GLP-1s, a pre-diabetes diagnosis strengthens your prior authorization case considerably. It demonstrates clear medical necessity for weight management therapy and provides documented evidence of metabolic dysfunction.
Some insurance plans are now covering GLP-1 medications specifically for diabetes prevention in pre-diabetic patients, creating an additional coverage pathway beyond the standard weight-management indication.
Liv Body From $199/mo · Premium telehealth GLP-1 program with comprehensive metabolic support. Physician-supervised.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Eden Health $239/mo sema · Physician-led telehealth. Semaglutide from $239/mo. Free consultation, ongoing clinical support, cancel anytime.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Wellorithm From $199/mo · Algorithm-matched prescriber pairing for personalized GLP-1 therapy. Includes ongoing dose optimization.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
The Prevention Argument
The economic case for treating pre-diabetes with GLP-1 medications is compelling. The cost of managing type 2 diabetes — estimated at $9,600 per patient per year in direct medical expenses — dwarfs the cost of GLP-1 therapy. Intervening at the pre-diabetes stage can potentially prevent a lifetime of diabetes management costs.
This prevention-focused argument is driving both insurer coverage decisions and prescriber willingness to recommend GLP-1 therapy earlier in the metabolic disease progression.